Organon closed the sale of its JADA® System, a device that delivers rapid treatment for postpartum hemorrhage, to Laborie Medical Technologies on January 28, 2026. The transaction is valued at $440 million in cash, with an additional $25 million in earn‑outs tied to 2026 revenue targets, giving Organon a total of $465 million in proceeds that will be directed toward debt repayment.
The divestiture is a key element of Organon’s deleveraging plan, which was launched after the company’s 2021 spin‑off from Merck & Co. The $465 million cash infusion will reduce Organon’s long‑term debt load and free capital for investment in its core women’s health and general medicines pipelines. Interim CEO Joseph Morrissey said the sale “puts JADA in the hands of Laborie, well‑positioned to expand access to the system for mothers worldwide, and strengthens Organon’s balance sheet so we can pursue growth opportunities in women’s health biopharma.”
JADA® has shown strong revenue growth, with full‑year sales of $61 million in 2024, up from $20 million in 2022. The $440 million price tag represents a 6.5‑times trailing‑12‑month revenue multiple, underscoring the product’s market potential and the value Organon has built since acquiring it in 2021. The earn‑out structure aligns Laborie’s incentives with continued performance of the system in 2026.
Laborie, which has a history of acquiring innovative medical technologies, sees the JADA® System as a strategic fit that expands its obstetrics portfolio. The acquisition adds a proven device that addresses a critical global health need—postpartum hemorrhage, the leading cause of maternal mortality worldwide—while complementing Laborie’s existing product lines. The deal is part of Laborie’s broader strategy to grow its med‑tech offerings through targeted acquisitions.
Following the completion announcement, market participants reacted cautiously. Shares of Organon fell 1.2% at the close of the previous trading day, reflecting a short‑term adjustment to the new debt profile. Analysts noted that while the sale strengthens the balance sheet, it also removes a high‑growth asset from Organon’s portfolio, prompting a reassessment of future revenue growth expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.